This site is intended for Healthcare Professionals only.

NICE recommends new treatment for urothelial cancer


Share post:

The National Institute for Health and Care Excellence (NICE) has recommended a new treatment, ‘avelumab’, for metastatic urothelial cancer.

The recommendation follows a successful appeal by stakeholders against the previous recommendation made by NICE and further evidence from the company, including an increased commercial discount.

The draft guidance recommends avelumab (also known as Bavencio and made by Merck Serono) as maintenance treatment for adults with locally advanced or metastatic urothelial cancer that has not got worse after platinum-based chemotherapy.

Clinical trial evidence showed that avelumab increases both how long people live and the length of time before their disease gets worse compared with best supportive care alone.

Urothelial cancer is a type of bladder cancer and is three to four times more common in men. Around one in 50 men and one in 133 women will be diagnosed with bladder cancer in their lifetime. The majority of cases occur in people aged over 60. The main risk factor for bladder cancer is increasing age, but smoking and exposure to some industrial chemicals also increases the risk.

Helen Knight, interim director for medicines evaluation at NICE, said: “People with locally advanced or metastatic urothelial cancer often have a poor quality of life and a poor prognosis. Avelumab is a promising drug which has the potential to extend life. The committee recognised there are few treatments available to people with this form of cancer, many of whom have to wait until their disease gets worse before they are able to have immunotherapy or further courses of chemotherapy.”

Avelumab is a monoclonal antibody which attaches to a specific protein in the body known as PD-L1. Avelumab works by binding to the PD-L1 protein and blocks its effect. This allows the immune system to attack tumour cells.


Please enter your comment!
Please enter your name here

Current Issue March 2024

Related articles

Head lice cases on the rise across the UK, warns Superdrug

If lotions or sprays prove ineffective, consulting a pharmacist about alternative head lice treatments is recommended Parents are...

Gender identity services: GPhC publishes new resource for pharmacy professionals

The regulatory body sets out questions that pharmacy professionals should ask themselves when providing gender identity care  The General...

NHS patient safety initiative: 143 hospitals across England to roll out Martha’s Rule

This programme has the opportunity to truly transform “patient care and safety” NHS England has confirmed the initial sites...

Why You Shouldn’t Delay in Filing a Medical Malpractice Claim

When faced with the unfortunate situation of medical malpractice, it’s understandable that you may feel overwhelmed and uncertain...